Does Tigecycline Work Against MRSA?
Tigecycline, a glycylcycline antibiotic, shows in vitro activity against many MRSA strains due to its ability to bypass common tetracycline resistance mechanisms like efflux pumps and ribosomal protection. MIC90 values for MRSA typically range from 0.5–2 mcg/mL, indicating susceptibility for most isolates.[1][2] Clinical data from trials like TEST (2004–2007) reported microbiological eradication rates of 80–90% for complicated skin/skin structure infections (cSSSI), including MRSA cases.[3]
FDA and Label Indications for MRSA
Tigecycline is FDA-approved for cSSSI and complicated intra-abdominal infections (cIAI) in adults, where MRSA is a common pathogen in skin infections. The label notes activity against MRSA in these settings, but it's not specifically approved as first-line for MRSA pneumonia or bacteremia due to limited data and higher failure rates in ventilator-associated pneumonia.[4][5] Guidelines from IDSA (2011 for skin infections) list it as an alternative for MRSA cSSSI when vancomycin or daptomycin aren't options.[6]
When Is Tigecycline Used for MRSA?
Clinicians use tigecycline off-label for multidrug-resistant MRSA in polymicrobial infections, osteomyelitis, or when patients can't tolerate beta-lactams, vancomycin, or linezolid. Case series report success in MRSA prosthetic joint infections and endocarditis adjunct therapy, with cure rates around 70%.[7] It's often reserved for severe cases due to its bacteriostatic action and dosing (100 mg IV load, then 50 mg q12h).
Limitations and Failure Risks
Tigecycline has higher mortality risk in some meta-analyses (OR 1.28 for all-cause death), particularly in severe sepsis or pneumonia, leading to an FDA warning in 2010 and 2013.[8] For MRSA bloodstream infections, clearance rates lag behind daptomycin (60–70% vs. 85–90%). Resistance emerges via mutations in ribosomal protein L3 or efflux, affecting 5–10% of clinical MRSA isolates.[9] Suboptimal lung penetration limits pneumonia use.
How Does Tigecycline Compare to Standard MRSA Treatments?
| Treatment | MRSA Activity | Key Advantages | Key Drawbacks vs. Tigecycline |
|-----------|---------------|----------------|-------------------------------|
| Vancomycin | High (MIC ≤2 mcg/mL for most) | First-line, cheap, IV | Nephrotoxicity, slow kill |
| Daptomycin | High | Bactericidal, good for bacteremia | Inactivated by surfactant (pneumonia failure) |
| Linezolid | High | Oral option, lung penetration | Thrombocytopenia, resistance |
| Tigecycline | Moderate-high | Broad spectrum (VRE, Acinetobacter too) | Bacteriostatic, high mortality signal, IV-only |
Tigecycline covers anaerobes and gram-negatives better, suiting mixed infections, but lacks bactericidal activity needed for endocarditis or high-inoculum infections.[10]
What Do Guidelines Say Today?
2023 IDSA guidelines for MRSA favor vancomycin or daptomycin for bacteremia; tigecycline is not recommended routinely due to mortality data. For cSSSI, it's an alternative if isolates are susceptible. European guidelines (ESCMID) similarly de-emphasize it post-2010.[11][12] Check local antibiograms—tigecycline susceptibility exceeds 90% in many US hospitals.[13]
[1] PubMed: Tigecycline activity against MRSA
[2] JAC: MIC data
[3] Clin Infect Dis: TEST program
[4] FDA Label: Tygacil
[5] IDSA 2011 Skin Guidelines
[6] Ibid.
[7] Antimicrob Agents Chemother: Case series
[8] FDA Warning
[9] Emerg Infect Dis: Resistance
[10] Clin Microbiol Rev: Comparisons
[11] IDSA 2023 MRSA Update
[12] ESCMID Guidelines
[13] SENTRY Surveillance